CStone Pharmaceuticals today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental new drug application (sNDA) of selective RET inhibitor GAVRETO® (pralsetinib) for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC). The approval expanded the labeled indications of GAVRETO in China to include adult…
eTurboNews članki so samo za naročnike. Naročnina je BREZPLAČNA.
Naročniki se prijavijo tukaj Kliknite tukaj, če se želite BREZPLAČNO naročiti
Naročniki se prijavijo tukaj Kliknite tukaj, če se želite BREZPLAČNO naročiti
KAJ VZETI IZ TEGA ČLANKA:
- The approval expanded the labeled indications of GAVRETO in China to include adult….
- CStone Pharmaceuticals today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental new drug application (sNDA) of selective RET inhibitor GAVRETO® (pralsetinib) for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC).
- eTurboNews članki so samo za naročnike.
